novo glp 1 pill Oral GLP-1 Wegovy chases approval in obesity The FDA-approved GLP-1 pill for

Appetite may feel normal or slightly reduced

Typical patterns include: Rapid initial loss (first 4-6 weeks), much of which is water and glycogen Steady loss during mid-protocol (weeks 6-24) Plateaus lasting 1-3 weeks that resolve spontaneously Slower deceleration as you approach new equilibrium weight If you hit a plateau on tirzepatide that persists beyond 4-6 weeks at maximum dose, the tirzepatide troubleshooting guide covers the most common causes and solutions

Follow-up is important, particularly if symptoms worsen after a dose increase or do not respond to conventional tips

doi: 10.1111/dom.12605 222 KristensenSLRrthRJhundPSDochertyKFSattarNPreissDet al

In clinical practice, tirzepatide has become an important option because dual-receptor activity may help some patients achieve substantial weight loss when medically appropriate

Red-flag symptoms that require evaluation beyond "it's the medication" The decision tree: manage at home vs call your provider vs seek emergency care Does birth control interaction matter